Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-23T10:12:29.752Z Has data issue: false hasContentIssue false
  • English
  • Français

Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma

Published online by Cambridge University Press:  18 June 2018

Cristiane Decat Bergerot Open the ORCID record for Cristiane Decat Bergerot [Opens in a new window] ,
Karen Lynn Clark ,
Kimlin Tam Ashing ,
Paulo Gustavo Bergerot ,
Richard Obenchain ,
Nazli Dizman ,
JoAnn Hsu ,
Errol Philip ,
Matthew Loscalzo  and
Sumanta Kumar Pal
Cristiane Decat Bergerot
Affiliation:
Department of Medical Oncology & Experimental Therapeutics, City of Hope, Duarte, CA
Karen Lynn Clark
Affiliation:
Department of Medical Oncology & Experimental Therapeutics, City of Hope, Duarte, CA
Kimlin Tam Ashing
Affiliation:
Department of Population Sciences, City of Hope, Duarte, CA
Paulo Gustavo Bergerot
Affiliation:
Department of Medical Oncology & Experimental Therapeutics, City of Hope, Duarte, CA
Richard Obenchain
Affiliation:
Department of Supportive Care Medicine, City of Hope, Duarte, CA
Nazli Dizman
Affiliation:
Department of Medical Oncology & Experimental Therapeutics, City of Hope, Duarte, CA
JoAnn Hsu
Affiliation:
Department of Medical Oncology & Experimental Therapeutics, City of Hope, Duarte, CA
Errol Philip
Affiliation:
The Notre Dame Laboratory for Psycho-Oncology Research, University of Notre Dame, Notre Dame, IL
Matthew Loscalzo
Affiliation:
Department of Supportive Care Medicine, City of Hope, Duarte, CA
Sumanta Kumar Pal*
Affiliation:
Department of Medical Oncology & Experimental Therapeutics, City of Hope, Duarte, CA
*
Author for correspondence: Sumanta K. Pal, M.D., Department of Medical Oncology & Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Limited research exists examining the biopsychosocial experience of patients diagnosed with metastatic renal cell carcinoma (mRCC), a disease commonly associated with a poor prognosis. The purpose of this study was to describe rates and types of distress in mRCC patients and explore the relationship between distress and overall survival.

Method

A cohort of 102 patients with mRCC treated at a single institution was assessed by a touch screen–based instrument comprising 22 core items spanning physical, practical, functional, and emotional domains. Association between biopsychosocial distress and clinicopathologic criteria was interrogated. Overall survival was compared between patients with low distress versus high distress.

Result

High rates of distress (20.7%) were found among patients newly diagnosed with mRCC. Among those domains contributing to distress, pain, fatigue, and financial comorbidity were the most commonly reported by patients with mRCC. A trend toward poorer overall survival in those patients with high distress versus low distress was observed among mRCC patients.

Significance of results

Based on data from a relatively large sample of patients, this study provides the first specific insights into the potential impact of biopsychosocial distress and outcomes among patients with mRCC.

Keywords

Kidney cancermetastatic diseasedistress screeningoverall survivalbiopsychosocial distress
Type
Original Article
Information
Palliative & Supportive Care , Volume 17 , Issue 3 , June 2019 , pp. 353 - 355
Copyright
Copyright © Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brintzenhofe-Szoc, KM et al. (2009) Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50(4), 383–391.10.1176/appi.psy.50.4.383Google Scholar
Carlson, LE, Waller, A, and Mitchell, AJ (2012) Screening for distress and unmet needs in patients with cancer: review and recommendations. Journal of Clinical Oncology 30(11), 1160–1177.10.1200/JCO.2011.39.5509Google Scholar
Clark, K et al. (2016) Biopsychosocial problem-related distress in cancer: examining the role of sex and age. Psychooncology 26(10), 1562–1568.10.1002/pon.4172Google Scholar
Conley, CC et al. (2016) Modafinil moderates the relationship between cancer-related fatigue and depression in 541 patients receiving chemotherapy. Journal of Clinical Psychopharmacology 36(1), 82–85.10.1097/JCP.0000000000000442Google Scholar
Guy, GP Jr et al. (2017) Economic burden of chronic conditions among survivors of cancer in the United States. Journal of Clinical Oncology 35(18), 2053–2061.10.1200/JCO.2016.71.9716Google Scholar
Heng, DY et al. (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology 14(2), 141–148.10.1016/S1470-2045(12)70559-4Google Scholar
Lowery, AE et al. (2012) Validation of a needs-based biopsychosocial distress instrument for cancer patients. Psychooncology 21(10), 1099–1106.10.1002/pon.2008Google Scholar
McFarland, DC et al. (2018) Prevalence of physical problems detected by the distress thermometer and problem list in patients with breast cancer. Psychooncology 24(10), 1217–1346.Google Scholar
Motzer, RJ, McCann, L, and Deen, K (2013) Pazopanib versus sunitinib in renal cancer. New England Journal of Medicine 369(20), 1970.10.1056/NEJMoa1303989Google Scholar
Onitilo, AA, Nietert, PJ, and Egede, LE (2006) Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. General Hospital Psychiatry 28(5), 396–402.10.1016/j.genhosppsych.2006.05.006Google Scholar
Parker, PA et al. (2003) Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psychooncology 12(2), 183–193.10.1002/pon.635Google Scholar
Pirl, WF et al. (2012) Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care. Journal of Clinical Oncology 30(12), 1310–1315.10.1200/JCO.2011.38.3166Google Scholar
Shih, YC et al. (2011) Economic burden of renal cell carcinoma: part I–an updated review. Pharmacoeconomics 29(4), 315–329.Google Scholar